Insights from mouse models of colitis

Journal of Leukocyte Biology

Volumn 67, Issue 3, 2000, Pages 267-278

  Boismenu, R ^a   Chen, Y ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cytokines; Inflammation; Intestine; Keratinocyte growth factor; T cells; Tumor necrosis factor

Indexed keywords

CD4 ANTIGEN; CYTOKINE; CYTOKINE ANTIBODY; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; INTERLEUKIN 12 ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL MODEL; COLITIS; COLON DISEASE; EXPERIMENTAL MODEL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALIA;

EID: 0033822405     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.67.3.267     Document Type: Review

References (153)

1. Regional ileitis
2. Historical aspects of inflammatory bowel disease
3. Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis
4. Inflammatory bowel disease: Etiology and pathogenesis
5. Experimental models of inflammatory bowel disease
6. Experimental models to study molecular mechanisms underlying intestinal inflammation
7. Animal models of inflammatory bowel disease - An overview
8. The immunologic basis of inflammatory bowel disease
9. Crohn's disease. New concepts of pathogenesis and current approaches to treatment
10. Chronic intestinal inflammation: An unexpected outcome in cytokine or T cell receptor mutant mice
11. T cells and cytokines in Crohn's disease
12. Mucosal immunoregulation and inflammatory bowel disease: New insights from murine models of inflammation
13. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease
14. Optimizing therapy for inflammatory bowel disease
15. Inflammatory bowel disease workshop. Vail, Colorado, March 22 and 23, 1998. Maintenance therapy in IBD
16. Immunotherapy of Crohn's disease
17. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
18. Experimental production of diffuse colitis in rats
19. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice
20. Hapten-induced model of chronic inflammation and ulceration in the rat colon
21. Antibodies to interleukin 12 abrogate established experimental colitis in mice
22. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4
23. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice
24. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain
25. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
26. Interleukin-10-deficient mice develop chronic enterocolitis
27. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice
28. Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice
29. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice
30. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin
31. + T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice
32. + T cells
33. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice
34. Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis
35. Severe colitis in mice with aberrant thymic selection
36. + T cells are responsible for murine interleukin-2-deficient colitis
37. + T cells in immunodeficient, adoptive hosts depends on their state of activation, IL-12 responsiveness, and CD45RB surface phenotype
38. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdrla, spontaneously develop colitis
39. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa
40. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells
41. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils
42. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
43. Structure and expression of murine intestinal trefoil factor: High evolutionary conservation and postnatal expression
44. Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes
45. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway
46. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor
47. Mice lacking transforming growth factor alpha have an increased susceptibility to dextran sulfate-induced colitis
48. Transforming growth factor alpha protection against drug-induced injury to the rat gastric mucosa in vivo
49. Increased production of transforming growth factor alpha following acute gastric injury
50. T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice
51. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice
52. + T cells are important for the balance between protective and pathogenic cell-mediated immunity
53. T cells in inflammatory bowel disease: Protective and pathogenic roles
54. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice
55. Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses
56. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines
57. Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice
58. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice
59. Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis
60. Combination therapy of pentoxyfylline and TNF alpha monoclonal antibody in dextran sulphate-induced mouse colitis
61. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice
62. + T cell-transplanted scid mouse model of colitis
63. Role of tumor necrosis factor (TNF) in the pathogenesis of colitis in mice
64. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
65. IL-12, but not IFN-gamma, plays a major role in sustaining the Chronic phase of colitis in IL-10-deficient mice
66. Induction and prevention of colonic inflammation in IL-2 deficient mice
67. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12
68. Immunohistochemical and immuno-electron-microscopic detection of interferon-gamma-inducing factor ('interleukin-18') in mouse intestinal epithelial cells
69. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells
70. Bioactive IL-18 expression is up-regulated in Crohn's disease
71. IL-18 is a potent coinducer of IL-13 in NK and T cells: A new potential role for IL-18 in modulating the immune response
72. Defective NK cell activity and Th1 response in IL-18-deficient mice
73. Cutting edge: Generation of IL-18 receptor-deficient mice: Evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor
74. + T cells
75. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation
76. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
77. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease
78. Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity
79. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis
80. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease
81. Genetic analysis of susceptibility to dextran sulfate sodium-induced colitis in mice
82. Hapten-induced model of murine inflammatory bowel disease: Mucosa immune responses and protection by tolerance
83. Inflammatory bowel disease: An immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus
84. T cell receptor-αβ-deficient mice fail to develop colitis in the absence of a microbial environment
85. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice
86. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon
87. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation
88. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism
89. Spontaneous inflammatory bowel disease in multiple mutant mouse lines: Association with colonization by Helicobacter hepaticus
90. Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease
91. +, CD45RB(high) T cells to SCID recipients
92. Generation of intestinal mucosal lymphocytes in SCID mice reconstituted with mature, thymus-derived T cells
93. Tolerance, danger, and the extended family
94. An innate sense of danger
95. II. The yin and yang of T cells in intestinal inflammation: Pathogenic and protective roles in a mouse colitis model
96. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12
97. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance
98. Control of immune pathology by regulatory T cells
99. + T cells: A population of T cells with immune regulatory activities in vitro
100. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation
101. Regulatory T cells and inflammatory bowel disease
102. + T-cell subset inhibits antigen-specifc T-cell responses and prevents colitis
103. + Th1-like responses
104. + T cells in a transfer model of colitis
105. An innate view of γδ T cells
106. Current concepts in mucosal immunity. III. Ontogeny and function of gamma delta T cells in the intestine
107. The immunobiology of T cells with invariant γδ antigen receptors
108. Changes in human mucosal γδ T cell repertoire and function associated with the disease process in inflammatory bowel disease
109. Increase of circulating γ/δ T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease
110. Increased frequency of abnormal γδ T cells in blood of patients with inflammatory bowel diseases
111. Homeostatic regulation of intestinal epithelia by intraepithelial γδ T cells
112. Modulation of epithelial cell growth by intraepithelial γδ T cells
113. Keratinocyte growth factor is required for hair development but not for wound healing
114. Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease
115. Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease
116. Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts
117. Crohn's disease
118. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
119. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation
120. Localisation of tumor necrosis factor alpha by immunochemistry in chronic inflammatory bowel disease
121. Tumor necrosis alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
122. Tumour necrosis factor and Crohn's disease
123. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
124. Randomized controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease
125. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
126. A role for TNFalpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
127. Tumor necrosis factor alpha antibody (inflixymab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
128. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
129. Neutralization of tumor necrosis factor by a soluble p75 receptor-Fc molecule (Enbrel(TM)) ameliorates chronic dextran sodium sulfate-induced colitis in mice
130. Computer-assisted rational design of immunosuppressive compounds
131. Characterization and biological significance of immunosuppressive peptide D2702.75-84 (EV) binding protein. Isolation of heme oxygenase-1
132. Studies with IL-10(-/-) mice: An overview
133. IL-7 deficiency prevents development of a non-T cell non-B cell-mediated colitis
134. The role of IL-10 in inflammatory bowel disease: 'Of mice and men'
135. Immunomodulation of Crohn's disease by interleukin-10
136. Successful treatment of experimental (TNBS) colitis by intranasal transfer of DNA encoding active TGF
137. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease
138. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1
139. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
140. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice
141. Beta2 integrin/ICAM expression in Crohn's disease
142. Activation of nuclear factor kappa B in inflammatory bowel disease
143. Nuclear factor kappaB is activated in macrophages and epithelial ceils of inflamed intestinal mucosa
144. Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7)
145. Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract
146. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor
147. Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice
148. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis
149. Reduced susceptibility of mice overexpressing transforming growth factor alpha to dextran sodium sulphate induced colitis
150. Protective effect of epidermal growth factor in an experimental model of colitis in rats
151. FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation
152. Cytokines, chaos, and complexity